THALES
8.6.2021 09:02:12 CEST | Business Wire | Press release
The award winning* Cinterion® IoT Suite Connectivity Activation by Thales greatly simplifies and digitalises cellular connectivity and the daily operations of industrial IoT device manufacturers and service providers. Based on standard eSIM technology, the new solution eliminates the need for IoT service providers to setup and run complex eSIM Remote Subscription Provisioning (RSP) platforms. It uses a single IoT eSIM that works with whichever mobile operator is selected by the device manufacturer or IoT service provider. The solution also enables resilient device connectivity and lifecycle management over the multi-year life spans of industrial solutions thereby delivering a reduction in Total Cost of Ownership for customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005041/en/
By 2025, 75 billion IoT devices will be connected with a potential market value of around $1.6 trillion. This not only brings unprecedented business opportunities, but also challenges such as how to streamline supply chain logistics for smart devices.
The solution simplifies manufacturing processes and logistics : In fact, device manufacturers no longer need to produce multiple product variants for deployment with different Mobile Network Operators (MNOs) in different countries. One product now fits all MNO networks as the IoT eSIM embedded in the industrial device can connect to any MNO network worldwide.
Thales system shortens device installation: Thanks to a remote activation process, the IoT eSIM automatically downloads the MNO profile that best suits the device location and connects to the network according to the service providers’ pre-defined business rules.
The solution guarantees network resilience and longevity : As networks and IoT applications evolve, the solution ensures reliable connectivity and business continuity by automatically switching to back-up connectivity providers removing the need for physical device updates.
“Thales leverages its unique expertise of cellular network infrastructure and collaboration with more than 400 mobile operators to simplify industrial IoT connectivity.The Thales Connectivity solution offers all the benefits of digitalisation and eSIM technology for the industrial IoT sector. With more than 25 years of constant innovation in IoT connectivity solutions, Thales enables the best total-cost-of-ownership and performance to its customers.” Frederic Deman, SVP of Analytics and IoT Solutions Business Line, at Thales.
“The IoT eSIM solution is a huge step forward for Aidon helping to ensure production flexibility and connectivity of our smart meters, even in rural areas, and all without the need for physical handling of SIMs,” said Petri Ounila, Director, IoT Devices, Aidon. “The solution co-developed with Thales provides a true operator selection and provisioning at any stage of the product lifetime. It is improving our ability to get smart meters connected, stay connected and adapt to new metering as-a-service business models.”
“The Thales Cinterion Connectivity Activation solution turns traditional methods of IoT device service provisioning and updating on its head, bringing new levels of service digitization, automation, Over-the-Air (OTA) management, and digital security to industrial IoT solutions” said Phil Sealy, Research Director at ABI Research . “Device manufacturers and service providers will no longer be tied to complex connectivity device design and logistics, thanks to a simplified and flexible approach. By easing the path to cellular connectivity and management, device manufacturers and service providers can redshift their focus toward innovation and scaling digital transformation for their customers.”
To learn more, join one of our virtual launch events on June 16 at 9:00 AM or 5:00 PM CEST.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security page
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom